[1]郎婧婧于丽华.典型国家DRG体系下新技术支付政策分析及启示[J].中国卫生质量管理,2022,29(04):021-24.[doi:10.13912/j.cnki.chqm.2022.29.4.06 ]
　LANG Jingjing,YU Lihua.New Technology Payment Policies under the DRG Payment System in Typical Countries and the Enlightenments[J].Chinese Health Quality Management,2022,29(04):021-24.[doi:10.13912/j.cnki.chqm.2022.29.4.06 ]
点击复制

典型国家DRG体系下新技术支付政策分析及启示
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第29卷
期数:
2022年04期
页码:
021-24
栏目:
关注DRG
出版日期:
2022-04-28

文章信息/Info

Title:
New Technology Payment Policies under the DRG Payment System in Typical Countries and the Enlightenments
作者:
郎婧婧于丽华
国家卫生健康委员会卫生发展研究中心
Author(s):
LANG Jingjing; YU Lihua
China National Health Development Research Center
关键词:
按疾病诊断相关分组; 新技术; 额外支付; 医疗服务价格项目
Keywords:
Diagnosis Related Group(DRG);  New Technology;  Additional Payment;  Fee Schedule
分类号:
R197.323
DOI:
10.13912/j.cnki.chqm.2022.29.4.06
文献标志码:
A
摘要:
在我国深入推进按疾病诊断相关分组（DRG）付费改革的背景下，设计DRG体系下适宜的新技术支付政策以及纳入DRG体系，是避免改革对技术创新产生负面影响的重要手段，也是DRG付费改革设计时需考虑的重要因素。文章在深入探讨技术创新与DRG支付体系关系的基础上，选取美国和德国作为典型国家，比较分析两国新技术支付政策的设计亮点，以及纳入DRG体系的流程，结合我国新技术支付的现状，提出新技术选择、额外支付范围、短期支付和纳入DRG支付体系等方面的政策建议。
Abstract:
Under the background of the reform of payment by Diagnosis-Related Group (DRG) in China, designing appropriate payment policies for new technologies under the DRG system and the process of incorporating them into the DRG system is an important means to avoid the negative impact of the reform on technological innovation, and also an important factor to be considered in the design of DRG payment reform.On the basis of exploring relationship between technical innovation and DRG payment system, typical countries were selected, the United States and Germany, after the comparative analysis between the two countries DRG design points of the new technology pay policies, and processes into the DRG system, combining with the present situation of the new technology payment in China, this paper puts forward some policy suggestions on new technology selection, additional payment scope, short-term payment and inclusion in DRG payment system.

参考文献/References:

［1］王海银，丛郦萱，彭 颖，等.我国新医疗技术的定价及支付优化策略探讨［J］. 中国卫生质量管理,2020,27（1）：105-108. ［2］国家卫生健康委员会.医疗技术临床应用管理办法［EB/OL］. （2018-08-13）［2021-10-10］.http://www.nhc.gov.cn/fzs/s3577/201809/e61d0999c95d4eb7b8a66 58bf6af149c.shtml. ［3］常欢欢，于丽华．我国新增医疗服务价格项目管理现状的研究与思考［J］．中国医院管理，2017，37（10）：33-35. ［4］ Busse R, Geissler A, Quentin W, et al. Diagnosis Related Groups in Europe-moving towards transparency,efficiency,and quality in hospitals［M］. England:Open University Press, 2011：131-145. ［5］张振忠，江芹，于丽华. 全国按疾病诊断相关分组收付费规范的总体设计［J］. 中国卫生经济，2017，36（6）：5-8. ［6］MedPAC. Accounting for new technology in hospital prospective payment system, in MedPAC Report to the Congress. Medicare Payment Policy［R］. Washington, D.C: Medicare Payment Advisory Commission,2002:1-35. ［7］ MedPAC. Payment for new techonologies in Medicare’s prospective payment system, in MedPAC Report to the Congress. Medicare Payment Policy［R］. Washington, D.C: Medicare Payment Advisory Commission,2003:1-50. ［8］CMS. Medicare program: payments for new medical services and new technologies under the acute care hospital IPPS:Final rule. Federal Register 66,no.174［R］. Washington,D.C:CMS，2001:46902-46925. ［9］Clyde AT, Bockstedt L, Farkas JA, et al. Experience with Medicare’s new technology add-on payment program［J］. Health Affairs，2008，27(6):1632-1641. ［10］Henschke C，Bumler M，Weid S，et al. Extrabudgetary (‘NUB’) payments: A gateway for introducing new medical devices into the German inpatient reimbursement system［J］.Journal of Management & Marketing in Healthcare，2010，3(2)：119-133. ［11］Ex P, Vogt V, Busse R, et al.The reimbursement of new medical technologies in German inpatient care: What factors explain which hospitals receive innovation payments［J］. Health Economics Policy and Law,2019,15(3):1-15. ［12］Hernandez J, Machacz SF, Robinson JC, et al. US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan［J］. Health Affairs，2015，34(2)：261-270. ［13］福建省医疗保障局，福建省卫生健康委员会.关于扩大疾病诊断相关分组（DRG）收付费改革试点的通知：闽医保〔2021〕60号［EB/OL］. （2021-07-05）［2021-10-10］.http://ybj.fujian.gov.cn/zfxxgkzl/fdzdgknr/zcwj/202107/t20210713_5647236.htm?ivk_sa=1024320u. ［14］何 青，江 芹，郎婧婧，等.典型国家和地区DRG实施过渡期经验探讨［J］. 中国卫生经济,2017,36（11）：93-96.

相似文献/References:

[1]吕国义.医院PACS系统发展趋势研究[J].中国卫生质量管理,2015,22(06):092.
[2]陶成琳 陈妍 林德南 刘建华.基于DRGs的深圳市医疗服务质量与绩效评价研究[J].中国卫生质量管理,2019,26(04):016.[doi:10.13912/j.cnki.chqm.2019.26.4.05]
[3]耿劲松 唐密 杨海 金春林 何江江.医院卫生技术评估研究方法的循证分析[J].中国卫生质量管理,2024,31(12):001.[doi:10.13912/j.cnki.chqm.2024.31.12.01]
　GENG Jinsong,TANG Mi,YANG Hai.Evidence-Based Analysis of Research Methods for Hospital-Based Health Technology Assessment[J].Chinese Health Quality Management,2024,31(04):001.[doi:10.13912/j.cnki.chqm.2024.31.12.01]

更新日期/Last Update: 2022-04-28